Abstract:Abstract Background and Aims Oxidative stress and activation of the renin-angiotensin system (RAS) due to chronic hyperglycemia are the pathogenesis of diabetic nephropathy (DN). Until now, therapy for DN has not shown satisfactory results. Rosmarinic acid (RA) which has antioxidant, anti-inflammatory, anti-fibrosis effects, and ARB which can inhibit RAS activation may have a synergistic effect to prevent DN progression. This study aims to determine the effect of inhibiting mesangial expansion in diabetic rat models after being given a combination of RA and ARB (candesartan or losartan). Method True experimental laboratory trial with randomized post-test only control group method on Rattus norvegicus strain Wistar rats. Diabetic rats were prepared by giving a high-fat diet (60% fat calories) and a single injection of 40 mg/kg streptozotocin. Mice were divided into 4 groups, each consisting of 4 rats: negative control (healthy rats); positive control (placebo diabetic rats); diabetic rats that received RA and candesartan; diabetic rats that received RA and losartan. The rat glomerulus was evaluated to assess mesangial expansion using ImageJ 1.48 software after 8 weeks of treatment by a pathologist blindly. Data analysis with One-way ANOVA and Tukey's post hoc tests. Results The results of the percentage of the mesangial matrix in the positive control group (81.49% ± 1.45) were higher than the negative control group (58.82% ± 0.99). The results of the percentage of the mesangial matrix in the RA + candesartan treatment group (61.56% ± 0.35) and the RA + losartan treatment group (62.28% ± 0.77) showed lower results than the positive control group, with the One-way ANOVA test results showing significant differences (p: 0.000). Tukey's post hoc tests showed the positive control group that received a high-fat diet and induced diabetes with STZ significantly increased mesangial expansion compared to negative control (MD: [22.66]; 95% CI: [20.62], [24.72]; p: 0.000). The RA + candesartan treatment group significantly inhibited mesangial expansion compared to the positive control (MD: [-19.92]; 95% CI: [-21.97], [-17.87]; p: 0.000), as well as the RA + losartan treatment group (MD: [-19.21]; 95%CI: [-21.26], [-17.16]; p: 0.000). The RA + candesartan treatment group showed a better effect in inhibiting mesangial expansion compared to the RA + losartan treatment group, but not significantly (p: 0.735). Conclusion The combination of rosmarinic acid with candesartan or losartan has the effect of inhibiting mesangial expansion in diabetic rats.

Inhibition of MCP-1/CCR2 Signaling Pathway is Involved in Synergistic Inhibitory Effects of Irbesartan with Rosuvastatin on Vascular Remodeling.

Irbesartan Attenuates Ischemic Brain Damage by Inhibition of MCP-1/CCR2 Signaling Pathway Beyond AT1 Receptor Blockade

Rosuvastatin Reverses Hypertension-Induced Changes in the Aorta Structure and Endothelium-Dependent Relaxation in Rats Through Suppression of Apoptosis and Inflammation.

Effects of Rosiglitazone on Serum Levels of Lipids and Inflammatory Factors in Atherosclerotic Rats

Beneficial effect of rosuvastatin on cardiac dysfunction is associated with alterations in calcium-regulatory proteins.

Effect of combination of calcium antagonist, azelnidipine, and AT1 receptor blocker, olmesartan, on atherosclerosis in apolipoprotein E-deficient mice

Synergistic protective effects of a statin and an angiotensin receptor blocker for initiation and progression of atherosclerosis

Effect Of Combined Treatment With Rosuvastatin And Protein Kinase C Beta 2 Inhibitor On Angiogenesis Following Myocardial Infarction In Diabetic Rats

[Effect of Irbesartan on Focal Cerebral Ischemia in Rats].

Statins exert differential effects on angiotensin II-induced atherosclerosis, but no benefit for abdominal aortic aneurysms.

Rosiglitazone inhibits angiotensin II-induced C-reactive protein production in human aortic endothelial cells through regulating AT 1 –ROS–MAPK signal pathway

No Synergistic Effect of Combined Olmesartan and Temocapril on Reversal of Left Ventricular Hypertrophy

Pleiotropic activation of endothelial function by angiotensin II receptor blockers is crucial to their protective anti-vascular remodeling effects

Effects of combination of pioglitazone and rosuvastatin on rat adventitial fibroblasts oxidization and inflammation induced by Ang Ⅱ

[Effects of Combination Therapy with Angiotensin I-converting Enzyme Inhibitor and Angiotensin 1 Receptor Antagonist on Ventricular Remodeling and Expression of Endothelial Nitric Oxide Synthase].

WITHDRAWN: Molecular Mechanisms of Irbesartan Suppressing Atherosclerosis in High Cholesterol-Diet Apolipoprotein E Knock-out Mice

Losartan, Captopril and Combined Administration on the Treatment of Atherosclerotic Renal Vascular Disease

DIFFERENT EFFECTS OF ANGIOTENSIN II AND ANGIOTENSIN-(1–7) ON ENDOTHELIAL VCAM-1 EXPRESSION DURING ATHEROSCLEROSIS

Irbesartan, an angiotensin II type 1 receptor blocker, inhibits colitis-associated tumourigenesis by blocking the MCP-1/CCR2 pathway

Therapeutic Assessment of Combination Therapy with a Neprilysin Inhibitor and Angiotensin Type 1 Receptor Antagonist on Angiotensin II–Induced Atherosclerosis, Abdominal Aortic Aneurysms, and Hypertension

#5018 EFFECTS OF CANDESARTAN COMPARED TO LOSARTAN ON INHIBITING MESANGIAL EXPANSION IN DIABETIC MODEL RATS RECEIVING ROSMARINIC ACID